EMA validates Gilead’s Type II variation application for Truvada for PrEP
1 February 2016 | By Victoria White
The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP...